Adolesent ADHD Study
A phase 4, randomized, double-blind, multicenter, parallel-group, active-controlled, dose-optimization safety and efficacy study of SPD 489 (Vyvanse) compared with OROS-MPH (Concerta) with a placebo reference arm, in adolescents aged 13-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD). SPD489-405
Psychiatry and Neurobehavioral Sciences
UVA Health System, Department of Psychiatry and Neurobehavioral Sciences, Division of Child and Family Psychiatry is conducting a research study of an investigational medication for ADHD in adolescents ages 13 – 17. The purpose of the study is to compare two investigational ADHD medications to see which one is more effective. The study involves blood draws, EKGs, a physical exam, psychiatric assessments and taking an investigational medicine/placebo (fake pill) every day for 8 weeks. There will be up to 10 visits over a period of up to 3 months each lasting about an hour. Compensation information: ? Study-related exams, tests and the study medication will be provided at no cost to qualified participants. ? Compensation for study completion may be up to $250. Contact Information: For more information please contact: • Leigh Gayle • 434.243.3678 or email@example.com • IRB-HSR# 16451 Principal Investigator: Dr. Vishal Madaan
Attention Deficit/Hyperactivity Disorder (ADHD)
Compensation for study completion may be up to $250.